| Recruiting | Proof of Concept Study on BP1.4979 Effect on Essential Tremor Essential Tremor | Phase 2 | 2025-09-17 |
| Recruiting | Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation Premature (Early) Ejaculation | Phase 2 | 2025-09-15 |
| Active Not Recruiting | Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents Autism Spectrum Disorder | Phase 2 | 2023-12-20 |
| Terminated | Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke Fatigue | Phase 2 | 2023-01-20 |
| Completed | Pilot Study on BP1.4979 Effect on Binge Eating Disorders Binge-Eating Disorder | Phase 2 | 2022-03-07 |
| Terminated | Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome Restless Legs Syndrome | Phase 2 | 2018-02-06 |
| Completed | Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment Alcohol Use Disorder | Phase 2 | 2018-01-09 |
| Completed | Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users Healthy, Drug Abuse | Phase 1 | 2017-03-15 |
| Withdrawn | A Trial Evaluating Pitolisant (BF2.649) in Alcohol Use Disorder Treatment Alcohol Abuse, Nervous System | Phase 2 | 2016-10-01 |
| Completed | Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Pitolisant in Healthy M Healthy Volunteers | Phase 1 | 2016-07-01 |
| Completed | Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind St Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy | Phase 3 | 2016-06-06 |
| Completed | Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA Excessive Daytime Sleepiness, Obstructive Sleep Apnea | Phase 3 | 2016-04-01 |
| Terminated | First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 Healthy Male Volunteers | Phase 1 | 2014-10-01 |
| Completed | Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules Healthy Male Volunteers | Phase 1 | 2013-09-01 |
| Completed | Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) Narcolepsy With Cataplexy, Excessive Daytime Sleepiness | Phase 3 | 2013-04-01 |
| Completed | Efficacy and Safety of BP1.4979 in Smoking Cessation Tobacco Addiction | Phase 2 | 2013-02-01 |
| Completed | Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) Narcolepsy | Phase 3 | 2012-09-01 |
| Completed | BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP. Obstructive Sleep Apnea, Excessive Daytime Sleepiness | Phase 3 | 2011-10-01 |
| Completed | BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS Obstructive Sleep Apnea, Excessive Daytime Sleepiness | Phase 3 | 2011-08-01 |
| Completed | Pharmacokinetics of BF2.649 in Renal Impairment Renal Impairment | Phase 1 | 2011-07-01 |
| Completed | Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) Narcolepsy, Cataplexy | Phase 3 | 2011-05-01 |
| Completed | Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. Treatment of Excessive Daytime Sleepiness in Narcolepsy | Phase 3 | 2010-11-01 |
| Completed | Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) Obstructive Sleep Apnoea, Excessive Daytime Sleepiness | Phase 2 | 2010-10-01 |
| Completed | Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease Parkinson's Disease | Phase 3 | 2010-03-01 |
| Completed | Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease Parkinson's Disease | Phase 3 | 2009-12-01 |
| Completed | Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy Narcolepsy, Cataplexy, Excessive Daytime Sleepiness | Phase 3 | 2009-10-01 |
| Completed | Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Narcolepsy, Excessive Daytime Sleepiness, Cataplexy | Phase 3 | 2009-05-01 |
| Completed | Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Diseas Excessive Daytime Sleepiness, Parkinson's Disease | Phase 2 | 2007-10-01 |
| Withdrawn | Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoe Excessive Daytime Sleepiness, Obstructive Sleep Apnea | Phase 3 | — |